Nayara
AI companions for patients to provide guidance and support between clinical appointments.
Website: https://www.nayara.ai/
Cover Block
Publicly reported
| Field | Value |
|---|---|
| Name | Nayara |
| Tagline | AI companions for patients to provide guidance and support between clinical appointments. [Tech.eu, November 2026] [Femtech World, November 2026] |
| Headquarters | London, UK [Tech.eu, November 2026] [Nstartup, November 2026] |
| Founded | 2024 [Crunchbase] |
| Stage | Pre-Seed [UK Tech News, November 2026] |
| Business Model | B2B [Tech.eu, November 2026] [Nstartup, November 2026] |
| Industry | Healthtech [Tech.eu, November 2026] [Femtech World, November 2026] |
| Technology | AI / Machine Learning [Tech.eu, November 2026] [Nayara.ai website] |
| Geography | Western Europe [Tech.eu, November 2026] |
| Growth Profile | Venture Scale [UK Tech News, November 2026] [StartupMag, November 2026] |
| Founding Team | Co-Founders (2) [UK Tech News, November 2026] [Nstartup, November 2026] |
| Funding Label | Pre-seed, total disclosed about $490,000 (estimated from reported £387,865 using rounded GBP/USD conversion) [UK Tech News, November 2026] |
| Lead Investor | SFC Capital [UK Tech News, November 2026] [Tech.eu, November 2026] |
Links
Publicly reported
- Website: https://www.nayara.ai/
Summary and Signal
PUBLIC Nayara builds AI companions for patients between clinical appointments, a narrow but credible wedge in care delivery that has begun to attract capital as providers look for ways to extend support without adding proportional staff load [Tech.eu, November 2026] [Femtech World, November 2026] [UK Tech News, November 2026]. The timing matters because the company announced a pre-seed round led by SFC Capital in November 2026, giving investors an early read on a team trying to position conversational AI as the patient-facing layer between visits rather than a generic administrative tool [UK Tech News, November 2026] [StartupMag, November 2026].
The public record is still thin, but the broad outline is consistent: Nayara is a London-based startup founded in 2024, selling on a B2B basis to hospitals, health systems, and medical-technology companies [Crunchbase] [Nstartup, November 2026]. Its product is described as guiding patients through pathway-specific questions, providing real-time support, and escalating potential issues to clinical teams, with early emphasis on breast-cancer support and adjacent workflows such as medication adherence, pre-operative preparation, appointment retention, and device onboarding [Nayara.ai website] [UK Tech News, November 2026] [Femtech World, November 2026].
That positioning is interesting because the differentiation, at least from what is publicly documented, sits less in the base model layer and more in workflow design, emotional-support framing, and clinical routing inside specific care pathways [Nayara.ai website] [Tech.eu, November 2026]. Nayara says one breast-cancer companion has supported hundreds of patients, but the company has not publicly named the health system or published independently verified outcomes, so traction should be treated as directional rather than proven at this stage [Nstartup, November 2026] [Konsulteer, November 2026].
The team appears to span product, commercial, and technical experience, though evidence quality is mixed. Public coverage names Gal Moore and Rami Kahan as co-founders, and profile data also identifies Eduard Rudyk and Yael Kfir as co-founders; Moore has been linked publicly to prior roles at Cogniteam, ThetaRay, and ZINC, while Kahan is presented in profile materials as having senior sales experience in global technology companies [UK Tech News, November 2026] [TechCrunch] [LinkedIn] [ContactOut].
Funding is modest but relevant for stage. UK Tech News reported the pre-seed at £387,865, approximately $490,000 (estimated) using the structured fact conversion provided in the source set, and multiple outlets corroborate SFC Capital as the lead investor even where the amount is not consistently repeated [UK Tech News, November 2026] [Tech.eu, November 2026] [StartupMag, November 2026].
Over the next 12 to 18 months, the main questions are straightforward: whether Nayara can turn early pathway-specific deployments into named enterprise references, whether it can show measurable clinical or operational outcomes, and whether emotional-support use cases can be translated into repeatable B2B buying motions across providers and medtech partners [Konsulteer, November 2026] [Femtech World, November 2026]. If those proofs emerge, the company could occupy a useful layer in oncology and other high-anxiety care journeys; if they do not, it risks remaining an interesting product concept without hard evidence of procurement durability.
Thinly sourced -- Core funding event is corroborated by multiple public outlets, but several material operating claims, founder-role details, and traction signals remain company-originated or single-source.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Pre-Seed |
| Business Model | B2B |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | Pre-seed, total disclosed approximately $490,000 [UK Tech News, November 2026] |
Company Overview
PUBLIC
Nayara is still early enough that the cleanest read is through the few facts that recur across public records: a London headquarters, a 2024 founding date, and a focus on conversational AI for patient support between clinical appointments [Crunchbase] [Nayara.ai website]. The company presents itself as building an AI layer for patient-healthcare interaction, with an initial emphasis on care guidance and support workflows rather than a broad hospital software stack [Nayara.ai website].
Public corporate naming also appears slightly more specific than the brand alone. Funding coverage tied to the November 2026 pre-seed identified the operating entity as GY Health Technology, trading as Nayara, which is useful context for diligence even though the company markets under the Nayara name [Nayara.ai website].
The public milestone record is short but coherent. Crunchbase lists Nayara as founded in 2024 and based in London, while the company website frames the product around real-time patient guidance and provider-facing risk flags and summaries [Crunchbase] [Nayara.ai website]. The first clearly reported financing milestone arrived in November 2026, when multiple outlets covered a pre-seed round led by SFC Capital; this section stays with the existence of the company and its timeline rather than funding detail, but the announcement is the first broad public marker that Nayara had moved from formation into external market visibility [Crunchbase].
One source, partially checked -- This section relies primarily on Crunchbase and the company website, with partial public corroboration on the trading name but limited independent corporate filing detail in the cited base.
The Product and the Stack
Public record plus analysis
Nayara is selling a narrow but commercially legible proposition: conversational AI companions that stay with patients between appointments, where provider capacity is thin and routine anxiety, adherence questions, and triage noise tend to accumulate [Tech.eu, November 2026] [Femtech World, November 2026]. Public descriptions present the product as software for hospitals, health systems, and medical-technology companies, with workflows aimed at answering protocol-specific patient questions, providing guidance and emotional support, and surfacing issues that should be routed back to clinical teams [UK Tech News, November 2026] [Nstartup, November 2026]. On its website, the company says the platform provides real-time AI guidance for patients alongside automated risk flags and summaries for care teams, and it frames one breast-cancer companion as delivering clinically accurate information while addressing fear and uncertainty in real time [Nayara.ai website].
The evidence on scope is directionally useful but still thin. Website and press materials describe use cases spanning breast-cancer support, medication adherence, pre-operative preparation, appointment retention, and medical-device onboarding, which suggests Nayara is positioning the core product as a configurable patient-engagement layer rather than a single-condition application [Nayara.ai website] [UK Tech News, November 2026] [Nstartup, November 2026]. A reported breast-cancer deployment has supported hundreds of patients, according to Nstartup, but the available public record does not name the provider customer, publish outcome data, or show a verified product demo, so the current read has to separate workflow intent from demonstrated clinical performance [Nstartup, November 2026] [Konsulteer, November 2026].
Because there are no verified engineering materials, technical architecture should be treated cautiously. The public language points to an LLM-based conversational system with escalation logic and provider-side summarization, but claims about the underlying stack, model choices, integrations, or compliance architecture are not substantiated in the available sources and should not be inferred beyond that surface description [Nayara.ai website] [Yael Kfir - Peaks Life Science | LinkedIn].
No independent source found -- This section relies primarily on company website language and startup press coverage, with no independently verified demo, technical documentation, or named deployment evidence in the cited public sources.
The Market They Are Entering
PUBLIC
The market matters because patient support between appointments is one of the clearer operational gaps in healthcare, but Nayara is entering it before the category has settled into a single budget line or a standard buyer motion [Tech.eu, November 2026] [Femtech World, November 2026]. Public sources describe the company as selling AI companions to hospitals, health systems, and medical-technology companies for use cases such as breast-cancer support, medication adherence, pre-operative preparation, appointment retention, and device onboarding [Tech.eu, November 2026] [UK Tech News, November 2026] [Nayara.ai website]. That points less to one neatly bounded market than to an overlap among digital patient engagement, virtual care support, clinical communication software, and condition-specific oncology navigation.
The hard part is that no cited third-party market report in the available record gives a direct TAM, SAM, or SOM for Nayara’s exact category. The cleaner public framing is analogous rather than precise: the company appears to sit inside broader digital patient engagement and care-navigation spending, with a narrower initial wedge in oncology support according to product and press descriptions [Femtech World, November 2026] [Nstartup, November 2026] [Nayara.ai website]. Because the available evidence does not include named third-party sizing studies, investors should treat the present market picture as demand-shape analysis rather than a quantified category map.
| Market lens | Relevance to Nayara | Public support |
|---|---|---|
| Digital patient engagement | Core category analogue, since Nayara focuses on communication and support between visits | Product and funding coverage describe patient guidance, check-ins, and routine question handling [Tech.eu, November 2026] [UK Tech News, November 2026] |
| Clinical triage and escalation tools | Relevant because the product is described as flagging issues and routing them to provider teams | Workflow described in coverage and on the company site [UK Tech News, November 2026] [Nayara.ai website] |
| Oncology navigation and survivorship support | Relevant initial wedge, given the breast-cancer companion highlighted in coverage | Breast-cancer support is the most concrete public use case surfaced [Femtech World, November 2026] [Nstartup, November 2026] |
| Medtech patient onboarding | Adjacent market if device makers use the platform for adherence and onboarding | This use case is named in the available product descriptions [Nayara.ai website] [Tech.eu, November 2026] |
The table suggests Nayara is not pursuing a single monolithic software market. It is closer to a workflow layer that could be sold into several adjacent budgets, which expands surface area but can lengthen category education and procurement.
Demand drivers are visible even without a formal sizing model. The company’s public positioning centers on what happens after the patient leaves the clinic: routine questions still arrive, adherence still slips, anxiety remains high, and provider teams do not have the labor capacity to answer every low-acuity interaction in real time [Tech.eu, November 2026] [Femtech World, November 2026] [Nayara.ai website]. If the software can absorb a share of those interactions while escalating higher-risk signals, it maps to two persistent buyer pressures, staff shortages and the need to maintain patient engagement without adding equivalent headcount [UK Tech News, November 2026] [StartupMag, November 2026].
The adjacent and substitute markets matter because they shape both competition and budget access. Some buyers may view this as part of CRM-style patient messaging, some as a virtual nurse extension, and some as a condition-specific care-navigation tool, especially in oncology [Femtech World, November 2026] [Tech.eu, November 2026]. Others may treat human call-center outreach, nurse navigators, or static education content as the substitute, which means Nayara will likely need to prove not only engagement, but also safety, escalation quality, and operational savings before budgets consolidate around AI companions.
Regulation and macro conditions cut both ways. The tailwind is straightforward: healthcare systems continue to search for labor-efficient ways to manage rising communication load and keep patients on pathway, particularly in areas where missed appointments, poor preparation, or low adherence create downstream cost [UK Tech News, November 2026] [StartupMag, November 2026]. The constraint is equally clear. Because Nayara is operating near clinical communication and protocol guidance, its commercial path will depend on validation, governance, and buyer comfort with AI-mediated patient interactions, which the company itself has said it plans to support through product development and clinical validation following the pre-seed round [Tech.eu, November 2026] [StartupMag, November 2026].
No independent source found -- This section relies primarily on company descriptions and funding coverage that outline use cases and buyer categories, but the available public record includes no cited third-party market sizing report for Nayara's exact category.
The Competitive Field
Competitive positioning
MIXED Nayara is positioning itself less as a general AI chatbot vendor and more as a workflow layer for patient support between appointments, a slot that sits between incumbent patient-engagement software and condition-specific navigation services [Nayara.ai website] [Tech.eu, November 2026] [UK Tech News, November 2026].
The immediate competitive map is narrower than the broad "digital health AI" label suggests. On one side are incumbents in hospital communication and patient engagement, which already own provider relationships and can add conversational features into existing portals, call-center workflows, and reminder systems. On another are disease-management and navigation programs, especially in oncology, that combine human support with software and may present a more trusted option for emotionally sensitive use cases. A third bucket is the substitute layer: hospitals can keep these interactions inside nurse triage, care coordination teams, or standard CRM tools rather than buying a dedicated AI companion product. The available public reporting confirms Nayara is selling to hospitals, health systems, and medtech companies, and that its current wedge includes breast-cancer support, medication adherence, pre-operative preparation, appointment retention, and medical-device onboarding, but it does not identify direct rival firms by name or document head-to-head wins [Nayara.ai website] [Nstartup, November 2026] [UK Tech News, November 2026].
Where Nayara may have an edge today is focus. The company is not describing a broad administrative AI stack; it is describing protocol-specific patient guidance, escalation, and routing in the periods when clinicians are absent from the interaction [Nayara.ai website] [UK Tech News, November 2026]. That focus can matter in healthcare procurement because buyers often prefer a clear first use case, particularly in oncology or perioperative pathways where missed questions and drop-off between visits have obvious operational costs. The edge is still perishable. Public evidence does not yet show named customers, exclusive distribution, proprietary clinical datasets, published outcomes, or regulatory milestones that would make the position hard to copy if larger patient-engagement vendors decide the category is attractive [Konsulteer, November 2026] [Femtech World, November 2026].
The main exposure is distribution and proof, not product narrative. An incumbent vendor with an existing hospital footprint could likely match the surface-level feature set faster than Nayara can build enterprise sales reach, while navigation providers and specialist oncology programs may have stronger trust with patients and clinicians in emotionally charged pathways. Nayara is also exposed to buyers treating this as an add-on feature rather than a new software category, especially if the purchase decision is owned by provider IT teams that already have engagement platforms in place. Public coverage also leaves an evidence gap around outcomes: the company says a breast-cancer companion has supported hundreds of patients, but the reporting does not name the deployment partner or independently verify clinical or economic results [Nstartup, November 2026] [Konsulteer, November 2026].
The most plausible 18-month scenario is a sorting of the category by clinical evidence and channel access rather than by model quality alone. Nayara is the likely winner if it can turn the early breast-cancer deployment into named references, repeatable pathway-specific outcomes, and at least one distribution anchor with a provider or medtech channel partner, because that would convert a promising workflow concept into something procurement teams can underwrite [Femtech World, November 2026] [StartupMag, November 2026]. Nayara is the likely loser if incumbent patient-engagement platforms fold comparable conversational support into existing contracts before it establishes those references, since the public record today does not show that it owns a channel, a moat in data, or a category-defining standard that would force buyers to adopt a standalone vendor [Tech.eu, November 2026] [Konsulteer, November 2026].
No independent source found -- This section relies mainly on company descriptions and funding coverage, with no named competitors or independently verified win-loss data in the public source set.
Opportunity
PUBLIC
The prize here is large if Nayara can become the patient-engagement layer that health systems and medtech companies trust between appointments, because that position sits close to care delivery, retention, and workflow routing rather than at the edge of consumer wellness [Tech.eu, November 2026] [UK Tech News, November 2026].
The headline opportunity is not simply an AI chatbot for patients. The more consequential outcome is a workflow system that hospitals, health systems, and device makers use to manage the long gaps where patients ask routine questions, need reassurance, miss preparation steps, or surface issues that should be escalated to a clinician [Tech.eu, November 2026] [Nayara.ai website] [UK Tech News, November 2026]. That framing matters because Nayara is positioning itself in operational terms, engage patients, answer protocol-specific questions, identify issues that need clinical attention, and route them to the appropriate provider team, rather than only as a content layer [UK Tech News, November 2026] [Nayara.ai website]. The public evidence is still early and mostly company-linked, but there is a plausible path from a single breast-cancer use case to broader pathway coverage if the product can show it reduces staff burden while keeping patients engaged between visits [Femtech World, November 2026] [Nstartup, November 2026].
The upside branches into a small number of identifiable growth paths. Each depends on execution that has not yet been proven publicly, but each is grounded in the use cases Nayara already cites and the buyer groups named in coverage.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Oncology wedge to multi-pathway platform | Nayara starts with breast-cancer support, then expands into medication adherence, pre-operative preparation, and appointment retention inside the same provider accounts | A named deployment or validation result in oncology gives buyers confidence to add adjacent pathways [Femtech World, November 2026] [StartupMag, November 2026] | The company already describes those pathway categories as target workflows, and funding coverage says proceeds will support clinical validation and commercial expansion [Nayara.ai website] [StartupMag, November 2026] |
| Embedded patient layer for medtech companies | Nayara becomes the default engagement companion bundled with medical devices or therapy programs, helping onboarding, education, and escalation | A partnership with a device maker or therapy vendor that needs ongoing patient support between touchpoints [Tech.eu, November 2026] [Nayara.ai website] | Public descriptions say Nayara sells not only to providers but also to medical-technology companies, and device onboarding is one of the stated use cases [Tech.eu, November 2026] [Nayara.ai website] |
| Clinical operations software with AI triage | Nayara wins on workflow efficiency, with summaries and risk flags becoming valuable to care teams, not just patients | Evidence that provider teams act on AI-generated flags and summaries inside existing care pathways [UK Tech News, November 2026] [Nayara.ai website] | The product claim already pairs patient guidance with automated risk flags and summaries for clinical teams, which points toward operational rather than purely educational value [Nayara.ai website] |
The table suggests the same core bet from three angles: if Nayara can attach itself to an existing clinical workflow, expansion can come from additional pathways, additional provider departments, or adjacent commercial channels such as medtech.
What compounding looks like is fairly clear even from the limited public record. Each successful pathway deployment can generate a reusable protocol library, a better understanding of which patient questions recur between appointments, and a stronger escalation logic for when a conversation should be handed to a care team [UK Tech News, November 2026] [Nayara.ai website]. If that works, the product becomes easier to deploy in the next pathway because the buyer is not purchasing a blank-slate model, but a configured operating layer for common patient-support motions. The early sign, modest but relevant, is that Nayara is already describing multiple workflow types beyond a single disease area and says a breast-cancer companion has supported hundreds of patients, although that usage figure remains company-linked and unverified by named customers or outcomes [Nstartup, November 2026] [Konsulteer, November 2026].
The size of the win is hard to benchmark cleanly from the current source set because no public market-sizing report or direct public comparable was supplied here. Even so, the upper-end outcome is intelligible: if Nayara became embedded across provider and medtech workflows as the standard conversational layer for between-appointment care, it would resemble a system-of-engagement asset rather than a point chatbot [Tech.eu, November 2026] [Nayara.ai website]. In that scenario, not a forecast, the company could plausibly grow into a strategic acquisition target for a digital health platform, care-navigation vendor, EHR ecosystem participant, or medtech software consolidator that wants patient interaction data and workflow control between visits. The missing proof points are named customers, validated outcomes, and evidence of repeatable expansion, but the product ambition lines up with a part of healthcare that is large, labor-intensive, and still operationally fragmented according to the public framing of the problem Nayara is targeting [Femtech World, November 2026] [Tech.eu, November 2026].
No independent source found -- This section relies materially on company website claims and startup funding coverage, with no independently verified customer names, outcome data, or public market-size benchmark in the supplied sources.
Sources
Publicly reported
[Tech.eu, November 2026] SFC Capital backs Nayara’s AI platform for patient care | https://tech.eu/2026/11/05/sfc-capital-backs-nayaras-ai-platform-for-patient-care/
[Femtech World, November 2026] Nayara raises funding for AI breast cancer support | https://www.femtechworld.co.uk/news/cancer/nayara-raises-funding-for-ai-breast-cancer-support/
[UK Tech News, November 2026] GY Health Technology (t/a Nayara) secures £387,865 Pre-Seed funding led by SFC Capital | https://www.uktechnews.info/2026/11/05/gy-health-technology-t-a-nayara-secures-387865-pre-seed-funding-led-by-sfc-capital/
[Crunchbase] nayara.ai - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/nayara-ai
[StartupMag, November 2026] Nayara closes preseed round led by SFC Capital | https://www.startupmag.co.uk/funding/nayara-2026-pre-seed-funding/
[Nayara.ai website] Nayara | The Conversational & Emotional Layer for Patient-Healthcare Interaction | https://www.nayara.ai/
[Nstartup, November 2026] Nayara Raises Pre-Seed Funding Led by SFC Capital | https://nstartup.me/news/a2f4cc0e-4b46-4dc6-a3e2-986bb07e15e4
[Konsulteer, November 2026] Nayara Closes Pre-Seed Round for AI Patient Companions | https://www.konsulteer.com/article/uk-healthtech-nayara-closes-pre-seed-round-led-by-sfc-capital-for-ai-patient-companions
[TechCrunch] Attendee List - TechCrunch Tel Aviv | https://techcrunch.com/events/techcrunch-tel-aviv/attendee-list/
[LinkedIn] Gal Moore - Nayara.ai | LinkedIn | https://www.linkedin.com/in/galmoore/
Articles about Nayara
- Nayara's AI Companions Are Filling the Gaps Between Breast Cancer Appointments — The pre-seed startup is selling hospitals on AI agents that provide protocol-specific guidance and flag risks, aiming to become a standard layer in chronic care management.